Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer.
gastric cancer
herpes simplex virus
oncolytic virus
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
16 Feb 2021
16 Feb 2021
Historique:
received:
15
10
2020
accepted:
19
01
2021
entrez:
4
3
2021
pubmed:
5
3
2021
medline:
5
3
2021
Statut:
epublish
Résumé
Oncolytic virotherapy is an encouraging treatment using herpes simplex virus (HSV) for gastric cancer patients. To treat gastric cancer, we generated and evaluated the efficacy of an attractive type of oncolytic HSV expressing the suppressor of cytokine signaling 3 (SOCS3). We constructed a third-generation type of oncolytic HSV (T-SOCS3) arming with SOCS3 by a bacterial artificial chromosome (BAC) system. We examined the viral replicative intensification and oncolysis of T-SOCS3 for human gastric cancer cell lines
Identifiants
pubmed: 33659045
doi: 10.18632/oncotarget.27873
pii: 27873
pmc: PMC7899552
doi:
Types de publication
Journal Article
Langues
eng
Pagination
344-354Informations de copyright
Copyright: © 2021 Matsumura et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Anticancer Res. 2020 Apr;40(4):2247-2255
pubmed: 32234921
J Virol. 2004 Jun;78(12):6282-6
pubmed: 15163721
Anticancer Res. 2015 Oct;35(10):5201-10
pubmed: 26408678
Anticancer Res. 2017 Jul;37(7):3599-3605
pubmed: 28668851
Ann Surg Oncol. 2010 Mar;17(3):718-30
pubmed: 19915919
Virology. 2005 Jul 20;338(1):173-81
pubmed: 15939448
Anticancer Res. 2012 Jul;32(7):2985-9
pubmed: 22753762
Clin Cancer Res. 2005 Jan 1;11(1):351-60
pubmed: 15671566
Anticancer Res. 2018 Dec;38(12):6621-6629
pubmed: 30504370
Anticancer Res. 2018 Nov;38(11):6121-6126
pubmed: 30396927
Hum Gene Ther. 2011 Sep;22(9):1109-19
pubmed: 21361790
Oncotarget. 2019 Dec 24;10(67):7132-7141
pubmed: 31903171
Cancer Sci. 2016 Oct;107(10):1373-1379
pubmed: 27486853
Cancer Sci. 2018 Mar;109(3):600-610
pubmed: 29288515
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Oncogene. 2005 Sep 22;24(42):6406-17
pubmed: 16007195
Clin Cancer Res. 2003 Jul;9(7):2727-33
pubmed: 12855653
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6396-401
pubmed: 11353831
Mol Ther Oncolytics. 2020 Apr 08;17:205-215
pubmed: 32346610
Int J Cancer. 2013 Jan 15;132(2):485-94
pubmed: 22729516
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Gene Ther. 2000 May;7(10):867-74
pubmed: 10845725
Int J Cancer. 2012 Sep 15;131(6):1287-96
pubmed: 22095154
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Br J Cancer. 2015 Jul 28;113(3):433-42
pubmed: 26180928
Anticancer Res. 2019 Nov;39(11):6073-6086
pubmed: 31704835
Ann Oncol. 2019 Feb 1;30(2):250-258
pubmed: 30566590
Cancer Gene Ther. 2019 Nov;26(11-12):388-399
pubmed: 30607005
Clin Cancer Res. 2006 Nov 15;12(22):6737-47
pubmed: 17121894
Hum Gene Ther. 2006 Dec;17(12):1214-24
pubmed: 17107303
Cancer Res. 2005 Dec 1;65(23):10663-8
pubmed: 16322208
Annu Rev Immunol. 2000;18:143-64
pubmed: 10837055
Anticancer Res. 2019 Jul;39(7):3727-3737
pubmed: 31262899